I have been tracking purchase application data for over 14 years, and 2025 is likely the most confusing year for market participants that I have ever experienced. After today’s report of 22% year-over ...
Variety is the spice of life, and it may result in lower prices for your cell plan.
Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations, causing significant stock volatility. High trading volumes and sharp stock ...